Two doses per year could reshape HIV prevention, but price and licensing issues may limit scalability within the Brazilian public health system (SUS). The “quasi-vaccine” developed by Gilead Sciences arrives in Brazil with rare clinical evidence and global regulatory endorsement. But the geopolitics of voluntary licenses and the pricing logic in rich markets create a dilemma: how to remunerate innovation without turning prevention into a luxury incompatible with universality

How to revive the cooperative model that can transform Brazil into a biotechnology powerhouse When I received the invitation in 2005 to...

Brazil’s biodiversity, widely recognized as one of the richest in the world, offers a window of opportunity for innovative health...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...